» Articles » PMID: 26794710

Mesenchymal Stromal Cells and Immunomodulation: A Gathering of Regulatory Immune Cells

Overview
Journal Cytotherapy
Publisher Elsevier
Date 2016 Jan 23
PMID 26794710
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

Because of their well-recognized immunomodulatory properties, mesenchymal stromal cells (MSCs) represent an attractive cell population for therapeutic purposes. In particular, there is growing interest in the use of MSCs as cellular immunotherapeutics for tolerance induction in allogeneic transplantations and the treatment of autoimmune diseases. However, multiple mechanisms have been identified to mediate the immunomodulatory effects of MSCs, sometimes with several ambiguities and inconsistencies. Although published studies have mainly reported the role of soluble factors, we believe that a sizeable cellular component plays a critical role in MSC immunomodulation. We refer to these cells as regulatory immune cells, which are generated from both the innate and adaptive responses after co-culture with MSCs. In this review, we discuss the nature and role of these immune regulatory cells as well as the role of different mediators, and, in particular, regulatory immune cell induction by MSCs through interleukin-10. Once induced, immune regulatory cells accumulate and converge their regulatory pathways to create a tolerogenic environment conducive for immunomodulation. Thus, a better understanding of these regulatory immune cells, in terms of how they can be optimally manipulated and induced, would be suitable for improving MSC-based immunomodulatory therapeutic strategies.

Citing Articles

The role of the immune system in osteoarthritis: mechanisms, challenges and future directions.

Moulin D, Sellam J, Berenbaum F, Guicheux J, Boutet M Nat Rev Rheumatol. 2025; .

PMID: 40082724 DOI: 10.1038/s41584-025-01223-y.


Mesenchymal stem cells - the secret agents of cancer immunotherapy: Promises, challenges, and surprising twists.

Minev T, Balbuena S, Gill J, Marincola F, Kesari S, Lin F Oncotarget. 2024; 15:793-805.

PMID: 39576660 PMC: 11584032. DOI: 10.18632/oncotarget.28672.


Engineered Mesenchymal Stem Cells as Treatment for Cancers: Opportunities, Clinical Applications and Challenges.

Shamsul Kamal A, Fakiruddin K, Bobbo K, Ling K, Vidyadaran S, Abdullah S Malays J Med Sci. 2024; 31(5):56-82.

PMID: 39416732 PMC: 11477465. DOI: 10.21315/mjms2024.31.5.5.


Umbilical cord mesenchymal stem cells in ulcerative colitis treatment: efficacy and possible mechanisms.

Jiang X, Luo X, Cai C, Bai Y, Ding H, Yue H Stem Cell Res Ther. 2024; 15(1):272.

PMID: 39218946 PMC: 11368034. DOI: 10.1186/s13287-024-03878-y.


Human umbilical cord-derived mesenchymal stromal cells for the treatment of steroid refractory grades III-IV acute graft-versus-host disease with long-term follow-up.

Niu J, Li Y, Xu C, Sheng H, Tian C, Ning H Front Immunol. 2024; 15:1436653.

PMID: 39211037 PMC: 11357908. DOI: 10.3389/fimmu.2024.1436653.